For Immediate Release: March 3, 2017
513-579-9911 x 12523
Medpace Continues to Expand Scientific Leadership
Two New Medical Directors Join Medpace’s Therapeutically-focused Teams
CINCINNATI, OH — (March 3, 2017) – Medpace (MEDP), a scientifically-driven, global full-service clinical research organization (CRO) known for its strong therapeutic and regulatory expertise, announced the addition of two new physicians who will provide scientific and medical leadership in designing and conducting global clinical research. The addition of these therapeutic experts further strengthens Medpace’s unique physician-driven clinical development model which gives Sponsors specialized medical expertise throughout the design and management of their program.
Medpace is pleased to welcome the following experts to the Medical Affairs team:
Terence Eagleton, MBBS, BSc
Dr. Terence Eagleton is an accomplished pharmaceutical physician with an extensive and successful record working in a wide variety of therapeutic areas for numerous biopharmaceutical companies. Dr. Eagleton brings a strong background in clinical development to the Medpace team, with a specialty focus in Rare Disease and Orphan Indications. Prior to joining Medpace, his clinical research career consisted of global senior medical director level roles as well as a medical consultant for a variety of pharmaceutical companies where he advised and executed strategies largely in the development of innovative medicines for rare metabolic and endocrine diseases and orphan drug projects. Dr. Eagleton received his Bachelor of Medicine, Bachelor of Surgery (Honors) and his Bachelor of Science (Honors) in Physiology at the University College London.
Richard Kay, MBChB, PhD
Dr. Richard Kay is a Clinical Immunologist with a background in experimental immunology, molecular biology and immunogenetics. After obtaining his medical degree at the University of Manchester in England, he went on to gain a PhD at the University of Edinburgh. As a Global Medical Director at his previous companies, he was responsible for portfolio management and developing therapeutics in the respiratory and inflammatory disease areas. He joined the pharmaceutical industry after many years in clinical practice and academia and has published widely in internationally-recognized academic journals.
Medpace is a scientifically-driven, global full-service clinical research organization (CRO) providing Phase I-IV clinical development services for drug, biologic, and device programs. Medpace’s physician-led, high-science, and disciplined operating approach leverages regulatory and therapeutic expertise to accelerate the global development of safe and effective medical therapeutics across all major areas including hematology and oncology, cardiovascular, metabolic/diabetes, infectious disease, and neurology and psychiatry.